NEW YORK, NY –The Lenox Hill Hospital Brain Tumor and Vascular Centers within the Division of Neurosurgery treated a Brooklyn woman’s inoperable brain tumor with an experimental treatment using intra-arterial drug delivery.
John A. Boockvar, MD, director of the hospital’s Brain Tumor Center, spearheaded the study. The procedure was done as part of a Phase I/II clinical trial entitled, “Repeated Super-Selective Intra-arterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed Glioblastoma Multiforme.”
Rafael A. Ortiz, MD, the hospital’s director of neuro-endovascular surgery, and David J. Langer, MD, Lenox Hill’s director of neurosurgery, performed the procedure to treat a 60-year-old New Yorker who has a malignant, grade four-brain tumor called a glioblastoma. Due to its difficult location, it could not be removed with surgery.
Drs. Ortiz and Langer performed the hospital system’s first intra-arterial Xper-computed tomography angiogram (CTA), cerebral angiogram and intra-arterial infusion of the drug bevacizumab. A catheter was navigated from the femoral artery (artery that takes blood to the leg) to the arteries supplying blood to the tumor. Contrast dye was injected though the catheter while performing a rotational 3-D Xper CT (the first done in combination with this therapy) to accurately map the arteries supplying the tumor. Bevacizumab was delivered directly to the tumor instead of systemic therapy (intravenously), which the investigators believe will result in better drug penetration with fewer side effects.
“The purpose of the study is to learn whether bevacizumab given repeatedly, once every three months, through the arteries instead of the veins, is safe and effective when combined with chemoradiation in newly diagnosed patients with glioblastoma,” said Dr. Boockvar, principal investigator. “Additionally, one of the goals of the clinical trial is to determine if this treatment will help improve quality of life and extend survival.”
About the North Shore-LIJ Health System
One of the nation's largest health systems, North Shore-LIJ delivers world-class clinical care throughout the New York metropolitan area, pioneering research at The Feinstein Institute for Medical Research, a visionary approach to medical education highlighted by the Hofstra North Shore-LIJ School of Medicine, and healthcare coverage to individuals, families and businesses through the North Shore-LIJ CareConnect Insurance Co. Inc. North Shore-LIJ cares for people at every stage of life at 17 hospitals and more than 400 outpatient physician practices throughout the region. North Shore-LIJ’s owned hospitals and long-term care facilities house more than 6,000 beds, employ more than 10,000 nurses and have affiliations with over 9,400 physicians. With a workforce of about 48,000, North Shore-LIJ is the largest private employer in New York State. For more information, go to northshorelij.com.